PSMD9抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Jurkat cells, A549 cells, Human fetal kidney tissue, Primary antibody: P07569(PSMD9 Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07569(PSMD9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07569(PSMD9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The PSMD9 antibody is a crucial tool for studying the 26S proteasome, a large multiprotein complex responsible for targeted protein degradation in eukaryotic cells. PSMD9 (Proteasome 26S Subunit, Non-ATPase 9), also known as ASF1 or HSPC010. is a component of the 19S regulatory particle that recognizes ubiquitinated substrates and facilitates their unfolding and translocation into the proteasome’s catalytic core. This protein plays a role in maintaining cellular protein homeostasis, regulating processes like cell cycle progression, stress responses, and apoptosis.

Antibodies targeting PSMD9 are widely used in research to investigate proteasome assembly, function, and dysregulation in diseases. They enable detection of PSMD9 expression levels via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Studies utilizing these antibodies have linked PSMD9 to cancer progression, neurodegenerative disorders (e.g., Alzheimer’s disease), and autoimmune conditions, as proteasome dysfunction often underlies these pathologies.

Recent research highlights PSMD9's interaction with heat shock proteins and its potential role in modulating stress-adaptive pathways. Additionally, its overexpression in certain tumors has spurred interest in its utility as a biomarker or therapeutic target. Commercial PSMD9 antibodies are typically validated for specificity using knockout cell lines or siRNA-mediated knockdowns. Researchers must optimize experimental conditions due to the proteasome’s dynamic structure and tissue-specific expression variations.